Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Exclusion Criteria

• •1\. History of other malignant tumors within 2 years.
• •2\. Adverse events (except alopecia of any degree) of CTCAE \> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.
• •3\. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.
• •4\. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.
• •5\. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection.
• •6\. Heart-related diseases or abnormalities
• •7\. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.
• •8\. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.
• •9\. Live vaccine was given 2 weeks before the first medication.
• •10\. Women who are breastfeeding or pregnant.
• •11\. Hypersensitivity to the test drug and the ingredients.
• •12\. Other conditions assessed by the investigator to be unsuitable for participation in the study.